Evaluation of Patients With Liver Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001971
First received: July 12, 2006
Last updated: March 14, 2014
Last verified: September 2013
  Purpose

The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.

Patients participating in the study will first undergo a routine check-up as an outpatient. They will be asked to provide blood and urine samples for laboratory testing and will undergo an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and texture of the liver. After the initial visit subjects will be requested to follow-up once a year at the outpatient department for a similar check-up.

Additional tests may be requested throughout the study to provide information for other research studies and individual consent will be requested. These tests may include liver biopsies, skin biopsies, and / or specialized blood, plasma, and lymphocyte examinations.

Subjects that qualify for medications presently being studied may be offered the opportunity to benefit from experimental therapy.


Condition
Biliary Liver Cirrhosis,
Hemochromatosis
Hepatitis
Hepatolenticular Degeneration
Liver Disease

Study Type: Observational
Official Title: Evaluation of Patients With Liver Disease

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 99999999
Study Start Date: September 1991
Detailed Description:

This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various liver diseases such as acute and chronic hepatitis B, C, D and E, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, hemochromatosis, nonalcoholic steatohepatitis (NASH), noncirrhotic portal hypertension, hepatocellular carcinoma, and cryptogenic or poorly defined forms of chronic liver disease. Patients will initially be seen in the outpatient department and undergo a medical history and physical examination. They will have a series of blood and urine tests and abdominal ultrasound. Patients will then be followed in the outpatient department with visits every 1 to 12 months at which times they will undergo an interim medical history and brief examination and have blood studies taken. Liver biopsies will be done as a part of this protocol only if clinically indicated, and a separate consent form is provided. In addition, patients may be asked to undergo skin biopsy, plasmapheresis, lymphapheresis, genetic analysis, and Fibroscan procedures for research purposes only (immunologic, virologic, genetic, and other studies) and separate consent forms are provided. Patients qualifying for therapeutic or other trials of antiviral or immunomodulatory agents for their liver disease will be invited to enter such studies.

  Eligibility

Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

An indefinite number of patients with acute or chronic liver disease will be enrolled in this study. Criteria for selection will be the following:

Age above 2 years, male or female.

Evidence of acute or chronic liver disease on evaluation by the outside referring physician.

Absence of other significant medical illnesses that might interfere with prolonged follow up evaluation.

Willingness to enter the study.

EXCLUSION CRITERIA:

There are no specific reasons to exclude any patients from this protocol (exception below for plasmapheresis and lymphapheresis, and genetic analysis of serum samples) as it does not entail significant risk to the patient or excessive clinical burden to the Liver Diseases Branch. Patients who resolve their chronic liver disease, such as patients with chronic hepatitis B who become negative for HBsAg or patients with chronic hepatitis C who become negative for HCV RNA will continue to be followed despite lack of apparent disease or disability. This is to document that clearance of these hepatitis viruses is, indeed, associated with resolution of the liver disease and lack of long-term adverse effects. Because there are data suggesting that chronic HBsAg carriers who become HBsAg-negative and patients with chronic hepatitis C whose liver disease becomes inactive, can still develop long-term consequences of these diseases (especially hepatocellular carcinoma), following such patients is important.

Plasmapheresis and lymphapheresis: Patients will have to fulfill the criteria of the NIH Department of Transfusion Medicine regarding lymphapheresis donors. These include age (less that 65 years), weight (greater than 120 pounds), hematocrit (greater than 30 percent), blood pressure (less than 120 diastolic and greater than 90 systolic), and temperature (less than 37.5 degrees C). Because this is a research procedure to obtain reagents and assay materials, only patients who are active and relatively fit (i.e. not disabled from their liver disease) will be asked to undergo this procedure.

The only strict exclusion criterion will be active therapy with interferon. The basis for this exclusion was the findings from a retrospective analysis of a recent trial of recombinant human alpha interferon as therapy of chronic hepatitis B. In that study, the "response rate" or rate of clearance of hepatitis B virus with alpha interferon therapy was lower among patients who underwent lymphapheresis during therapy (48 percent) (p less than .01). Lymphapheresis performed before treatment did not seem to affect the outcome of interferon therapy. These findings were unexpected but have led us to avoid both plasmapheresis and lymphapheresis in patients receiving alpha interferon therapy. The reasons why lymphapheresis might interfere with a response to alpha interferon are to known, but probably relate to the importance of an intact, healthy immune system in the process of recovery from a chronic viral infection.

Fibroscan: Consecutive adult patients (ages 18 or older) with chronic liver disease who have had a liver biopsy performed within the previous 6 months or who are scheduled to undergo liver biopsy will be eligible for participation in this aspect of the study. Patients with liver biopsies that are inadequate for histological scoring or who have ascites will be excluded from this aspect of the study.

Genetic Analysis of Serum Samples: All adult subjects with a Hct of less than 30 and pediatric subjects with a Hct less than 26 will be excluded for phlebotomy that is necessary for isolation of DNA material from the blood cells. Inability to understand or sign informed consent will also exclude patients from this aspect of the study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001971

Contacts
Contact: Nancy Fryzek (301) 435-6122 nancy.fryzek@nih.gov
Contact: T. Jake Liang, M.D. (301) 496-1721 jakel@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Investigators
Principal Investigator: T. Jake Liang, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00001971     History of Changes
Other Study ID Numbers: 910214, 91-DK-0214
Study First Received: July 12, 2006
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Hemochromatosis
Hepatitis B
Hepatitis C
Hepatitis D
Chronic Cholestatic Syndromes
Primary Biliary Cirrhosis
Primary Sclerosing Cholangitis
Non-Alcoholic Steatohepatitis
Wilson's Disease
Liver Biopsy
Noncirrhotic Portal Hypertension
Liver Disease

Additional relevant MeSH terms:
Hemochromatosis
Hepatitis
Hepatitis A
Hepatolenticular Degeneration
Liver Cirrhosis
Fibrosis
Liver Cirrhosis, Biliary
Liver Diseases
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on July 20, 2014